Skip to main content

ImmunityBio, Inc Investor Event Transcript, Nov 16, 2026

ImmunityBio, Inc. (IBRX)

ImmunityBio said its BCG-naive trial met its endpoint with a p-value of 0.01 and plans to submit the SBLA this year; a recent approval expanded its label to papillary-only bladder cancer. AI summary

Investor Event Transcript 2026-11-16 For: 2026-12-31
Added on November 16, 2026

Conference Transcript - IBRX 2026-11-16

Roger Song, Analyst — Jefferies

All right. Welcome, everyone, to Jeffrey's 2026 Global Healthcare Conference in London. My name is Roger Song, senior, and this covers SMICAT biotech in the U.S. It is my pleasure to have the next five-side chat with Immunity Bio CEO, Rich Ancock. Welcome, Rich.

Richard Adcock, CEO

Thank you. Thank you. And first of all, I'd just like to say thank you to the Jeffrey's team for inviting us and for everybody here being present in the audience.

Roger Song, Analyst — Jefferies

Excellent. All right. Richard, why not you give us some overview of immunity bowel where you're coming from, what you're heading to, why you're excited about the future, and then particularly 2027, and then we do have a lot of the specifics we can talk about today.

Richard Adcock, CEO

Sounds great. You know, I think maybe one of the things to just let's just jump right into is Q3 as we look at what's happening there on those. And before I start on any of those, I'll just start almost just exactly like the last one. You know, we're not going to be providing any forward guidance for 2027 or what's happening in the current quarter on those pieces. Always refer everybody over to 10 Qs and 10 Ks for all of those pieces. But our Q3, we saw a nearly $49 million quarter, about a 53% growth year over year, slightly down over the prior quarter on those pieces, but about almost $144 million in sales for the first nine months of the year. And so we're really happy with that. But I think the bigger part of what happened in Q3 was really about the expansion. And because our first label that we have is the smallest part of bladder cancer, cis plus or minus, and end of October, plus or minus, is when we actually received, and we're the first in the world to actually receive this, our first in the United States to receive this, we now have the entire BCG unresponsive. So, CIS plus and minus papillary alone, and that's really a very important piece because if you look at that, and it's somewhere between two to three or four times larger market. But more important than what the market size is is what it does for the doctors, and I will tell you the day that we got that approval and probably over the couple of days that we got that approval, I probably had, I don't know, 20 physicians that would just call me personally and say congratulations, and they almost all said the same thing. Finally, I can get back to treating my patients the way I see them. I have high-risk patients that are either BCG naive or I have high-risk patients that are BCG unresponsive. And this nonsense about this CIS plus and minus just makes our billing office and our life miserable through those. They would usually go on to say, you know, instant CN is cool, but it doesn't actually address what payers really want is they want the FDA approval, so congratulations, and you've made our life a lot easier now. So we're really excited about that and happy to say that actually it's the second country that we got that in because the Emirates had previously approved it just prior to that with the full responsiveness on those. Beyond that, what's happening now, and what happened in the last quarter as well, is that we finished and met the endpoint that we reported out for our BCG Naive. So in high risk, you've got the unresponsive space, and you've got the BCG Naive. Kind of think of them as front line, second line, if you make it simple. And having met the endpoint for the NAIVE trial means, and we've been working on this in parallel, because you don't write one of these in a day, there's 700,000 or 800,000 pages, we will submit our BCG, the SBLA for BCG NAIVE yet this year. And so the team has really been going deep on that one, and we can go further into that in a little bit. So I think those are some of the things I would kind of start to talk about and focus everybody in on. Yeah, totally.

Roger Song, Analyst — Jefferies

Thanks, Rich. Maybe just on the three-year earnings, I believe, obviously, it's a very good number for nine months, year-on-year growth, and then as you start to launch Antiva. But that's the first time quarterly drawdown. So what's the reason? How concerned people should be, right? So maybe any comments you have there.

Richard Adcock, CEO

Thank you. The way I would look at it is, as we've always said on this one here, and it's really important to put things in context, the CIS plus or minus piece is a very small market. And there's a certain point when you're going to kind of run up against the headroom of that one. And what we've always said is we have to get out of the CIS-only market. We've got to get into that full BCG unresponsive market. So it was fortuitous, you know, that they gave it to us three months early, some would argue 10 months later than what we wanted it, because we wanted it prior on those pieces. But it's really important because that now gives us even more room to continue to grow inside of those. Obviously, you've got more people in there, you've got competition in there, you've got BCG that we're working through, and we can talk a little bit about that. But I think that's the way of looking at it is that the positive news of all of those pieces is that the market just got bigger for us. And right now we're alone in that pack.

Roger Song, Analyst — Jefferies

Excellent. That's literally my next question in terms of the papillary-only population. You just got approval in October, which is earlier than supposed to, the Puduva Day. And then what have you been seeing from that population in 3Q and then not in 3Q, but in the 4Q? And then how do you think about the growth driving next year into next year?

Richard Adcock, CEO

Yeah, so it's really probably one of the most important pieces for us. And I say that more from even in 2026, from 2027, we got it, let's just say at the end of October, to make it simple. And so I will tell you that we're already seeing sales from that one right in there. But it always takes a little bit of time when they get those because doctors got to work through their processes and all of those to be able to get it online. And so we'll see initial sales happening in Q4 through those. But the bigger piece of those we're expecting in 2027, because again, we're the only one standing alone with that piece. But we're also in that space, then submitting right now in for the naive setting on that one. And so I share that because when I'm working with physicians, and I've personally traveled with and met with hundreds or more physicians practices, I am always somebody who wants to be right out there and not hearing it filtered. I want to hear it right from a physician's mouth themselves. What they've told us is seeing that clear pipeline and clear path allows them when they're working through their algorithms is which one do I pick next? How do I work through that one? So getting that papillary only really gave them the confidence because there was many that didn't think we were going to get it. And we just smiled and said. We're going to get it. We're just not done. Because we had brought it forward the first time and they said, well, we need more data. It wasn't more clinical data they needed. We need to help them provide better context about what this immunotherapy really is doing in that space. And I'm very proud of the team for getting that done early.

Roger Song, Analyst — Jefferies

Got it. And then, you know, I know you're not giving us the guidance for next year yet, but, you know, you've been growing seven, eight million a quarter. So with the papillary, before you, you know, we can talk about a naive population for sure, but before you have the naive, you know, label or sales, how do you think about this growth going to back to you on track on the initial run rate or maybe even higher because the population is a little bit higher for the CIS?

Richard Adcock, CEO

Too soon to tell. I mean, because we're just literally in kind of the first single-digit days of having all those pieces. And, you know, that's what we'll be working on and providing more of that on those pieces. Okay.

Roger Song, Analyst — Jefferies

And then you are the only one who has the label for papillary. We know your competitor also got invited to submit the data. And then I think, I don't know about the data package because, you know, none of you have, I think you have the data from the single-arm trial. But, you know, but the NCC listing, they have that. So how the difference between the FDA label versus NCC listing and then how the payer can look at these two drugs?

Richard Adcock, CEO

The last part you said, I think is the most important is that obviously you need NCCN, but that alone is not enough, especially in this space, because the urologists don't want to take the risk. And we had that and we would talk with urologists that are absolutely tier one. They love us. They love the drug, and they would say, I'm not going to take the risk because it's not worth the cash flow if I get burned, and we've seen too many practices get burned on these types of pieces. Get the approval so we can see those, and that's what I was excited to see was on the approval. They literally said, okay, now I got a patient, and let's start through the process on all of these pieces. I think that's what's really most important is you've got to have both. Yes, they reported that they said they got invited through those. What I can tell you on ours is it wasn't just saying that, okay, it's all the same. We had to demonstrate to them that the patient population, as it related to our mechanism of action. And specifically on an immunotherapy approach, how it worked in there. And so I know right away, people always say, oh, they'll just copy and paste. I don't know. It's a different mechanism of action. Ours is not a chemo. Ours is an immunotherapy. So I don't know what they're going to do on those pieces. I know what we submitted. And I know the incredibly detailed scientific work that we had to bring forward. And that's what we have said. I don't, if I had a chemo, I don't know how I would position it that way, but that'll be on them.

Roger Song, Analyst — Jefferies

Yeah, the burden is on them to demonstrate if it's approvable or the benefit. And then you say you already have the sales front, the papillary only. And then how about the payer side? You already got the coverage, and then you get reimbursement from them.

Richard Adcock, CEO

And it goes back to the last question you asked, because when you have both FDA approval and instant CN, immediately CMS is covered. And so that's one of the benefits you get right there is you don't even have to go ask them. It just immediately kicks in and you get all of that. And so that opens up, you know, hundreds of millions of people right away. But everybody else is following because we had already been presenting to them prior to our approval. Here's what we're trying to bring forward for approval. And the payers were very open about this. I've personally met with many of the large payers, and the thing that I hear that I've personally heard from them is that what they appreciate about Anctiva is the long duration of response. I ran a multi or a large billion-dollar-plus health plan, and I would always say I didn't mind paying for expensive drugs. I hated paying for expensive drugs that didn't last. Because you put the money in, you don't get a return on those pieces. With Anctiva, and that's why we have even Kaiser is one of the people we have on those, and everybody knows Kaiser does amazing clinical care, but they always want to be, they're very cost conscious, and they're looking for those trade-offs so they can work through those. And I know that because I personally said in the meetings with Kaiser, they were fantastic there. Health economists, when we were working through those, they cued in on, of course, you got a response. How long is the duration? What are you seeing? How long is that? And that's what matters to them, and others as well, as we've met with the blues. And so we're seeing that quick uptick on those, you know, in the smaller label, we said we had 240 plus million lives covered. It'll rapidly fill in on that one. And that's why I say Q4 will see impact on it, but it's really going to be 2027 that we'll start to see more is what I'm expecting. But again, we're just kind of single digit days into this right now.

Roger Song, Analyst — Jefferies

Is that like a six month process? You can get a broader and broader as a six only or six plus minus papillary type of coverage?

Richard Adcock, CEO

Yeah, I think as we look at those, that's what we'll be seeing right now. And so there's on the payer side of that's going really well. The team under Matt Hillman, who lead our market access for the United States, have done just a remarkable job on trying to bring those forward and be very creative and meet the payers where they are. Because you can't say, here's my payer package, just drop them an email, because every payer has a different set of needs that they're looking at. Some want to look at it at a value base. Some want to look at it on this basis. And what I can tell you is that we've had great response because we've met with all of them. They like the drug. They know the drug. Now they say we get to do it on a bigger basis. And actually for them, that benefits them because now they got a broader patient population that they can impact.

Roger Song, Analyst — Jefferies

Yeah, got it. And then another piece is, yes, you have to approve the drug now. You have a couple maybe down the pipeline and then maybe in the near term. So how do you think about the physician feedback, the use experience, right? So you are already on the market and setting pretty good number. So how do you think about Anctiva usage versus, you know, all the practice and logistics compared to chemo and then some of the other immunotherapy?

Richard Adcock, CEO

I think that's really a differentiator. Obviously, I always emphasize duration, duration, duration, but Anctiva is the only, first, it's a chemo-free, second, it is the only of every drug that is either on trial or approved. It is administered by the nurse or the MA or the nurse practitioner. It's the exact same workflow as BCG, which has been used and is the standard of care for four decades. And so literally, and it's a joke, maybe not a good one, I call it shaken, not stirred, because they know how to do BCG. You literally add Anctiva. It's the same syringe, the same catheter, the same hold time. It's the same EMR schedule. They don't change anything. And so from the ability to deploy, it's very, very, very easy. Our medical affairs team come out. They do in-service trainings with them. And as I've said, I've been to many practices. I always, whenever I go out to a practice, make a point of this, and I've been doing this a long time, to spend time with the nurses. Both the nurses that are helping to manage the physician schedules, but also the BCG nurse, because he or she, as we'll go through those, are the ones who really do it, because inevitably, and I've seen this everywhere, they got this little drawer they pull out, and there's a notebook, and that's the BCG patients, and they know every one of those patients right there, and they know them by name, and because they have long-term relationships with these patients, because they're going through them over the course of treatment. And Dr. Murray from NYU was talking. She says, you know, when you get this, you and I are going to have a long-term relationship, but it's going to be a good one because we're going to get you through this process. And that's one that hit me early on as she was talking about that. And you see that happening. And so by not changing the workflow. And allowing the nurse to be able to do this allows the physician under the supervision, the nurse under the supervision of the physician, to be able to continue to do something else. And so their practice is growing. And that's something that's really important because everybody knows surgeons, physicians, and health care is under a lot of pressure. And so giving them something that matches their exact in-place workflow, but literally the only thing they have to do is order two drugs instead of one, and then do the admixture. And so it's pretty straightforward. And that's a real benefit that we have. And that others don't and won't. Yeah, I always say in this one, I would love Merck to be able to solve it. They keep saying they're going to. I welcome them to do that. It would be wonderful. But we haven't taken that approach. And the reason is that. BCG is a couple hundred dollars, right? So when they get their choice between something that's a blockbuster versus this, of course, it's playing out the way it is. Immunity Bio did two things in pretty short order. Right after we got our approval and not before, we reached out to Serum Institute and got the license, the global license exclusive for the recombinant BCG. And we did that because Serum Institute is the world's largest manufacturer of BCG. Most people think it's Merck and nothing against them. They're fantastic. But serum is actually the world's largest on those. And in doing that, what it allowed us to do was to be able to say, now we could have, I hate to say, almost an unlimited supply, but an unlimited supply. We brought that forward to the FDA and the FDA said, great, but we would like to approach this on an expanded access program. Which is a blessing and a curse because it takes some work for doctors to be able to do. It's not an authorized product. It's not a trial, but it's somewhere in the middle. And so we've got a lot of doctors that are doing that, but not every doctor is going to do that. Thank you. Just this last February at ASCO GU, we also saw the readout, and we were all anxiously waiting for this, which was the Tokyo BCG trial readout, which was TICE, Merck's TICE, versus the Tokyo BCG strain. That was a nine-plus-year trial they did. It was 1,000 patients in a head-to-head comparison, and I was hopeful, and I was literally, as we were getting the readout on all those pieces, I was going, just please be the same. I actually don't want it to be way stronger or way worse because it's easier to get to an approval if it's almost just a comparable on those pieces, and that's exactly what it was. Since that time, Dr. Sunsheng and myself flew to Japan. We negotiated and received the full rights to that, so we have the exclusive rights to the Tokyo BCG. We've had our teams in Japan multiple times because the great news is JBL, or Japanese BCG Laboratory, have been making that drug for four decades. It's been approved in Japan forever. The bad news for us is some of the file or all of the file was in Japanese, and I can't submit a Japanese file to the U.S. FDA, and so we paid to have that actually translated, and so the full dossier is now available to us. We have meetings with the FDA where we're working collaboratively with them. I don't have anything to report out in timing yet, but what I can say is that in addition to having that trial, JBL and SWOG or NIH have assigned that trial over to ImmunityBio. So as we sit here today, ImmunityBio is the IND holder for that 1,000-patient trial, and we've now converted it over. And so, you know, I'm looking forward to meeting with the agency to say, let's bring something else. Europe has six strains approved. In the United States, we've got one. And that just is one of those. So my real goal is literally to get both approved. If I had to guess, they'll probably approve Tokyo faster, given the size of that trial. But we're working with them on each of those. It's very important to us, obviously.

Roger Song, Analyst — Jefferies

Got it. And how many patients are already on the recombinant BCG?

Richard Adcock, CEO

Yeah, it's well over 1,000. And that's the pieces. It's complicated because an EAP generally are done in small numbers. And so when the FDA asked us to do this and said, can you just make it available to anybody, we just smiled and said, of course we can. But it is work, and the team at Immunity Bio that is managing that and bringing that out, kudos to them, because they're bringing that available in a much-needed shortage. Actually, the last two conferences they had, physicians, unprompted, were up on stage, and they were talking about it. And the one doctor stops, and he says, I just want to take a moment and acknowledge immunity bio, because without the EAP, we'd actually all be in, I think his exact words were deep doo-doo, because he says, we need that here. And so we need to support immunity bio through their work with Tokyo as well as recombinant, because we want them both out there. And so there's a lot of goodwill, but a lot of support from the physicians trying to bring this across the line.

Roger Song, Analyst — Jefferies

Yeah, we know urology like BCG, and it does save patients' lives. Okay, and then the top of the piece is the naive population, which is, you know, you say it's very much on track to submit a bill by the end of the year. You give us the top line press release, and without any detailed data, you know, people are asking, okay, why? You know, just tell us what's the thinking behind that, and then how, when, and how are we going to see the data?

Richard Adcock, CEO

So the first thing is I'm happy to tell you today that, which we did not previously report out, that trial met its endpoint, but it has a p-value of 0.01. And so that, you know, not only have we met it, but it's very strong statistical significance on those pieces. The reason we haven't provided the top-line numbers yet is that we're working with medical congresses to present all of that, and if you give out in a press release, then they don't want to give you a great speaking slot on those. And so it's a little, I hate to say it's a little bit of, you have to kind of hold some of it back so that you can get something really good, whether that's at ASCO GU or something sooner, we'll work through those. And we're having a lot of those conversations right now. But the more important one on those, and obviously a P value of 0.01 is just. I was thrilled when I saw that. You kind of quit looking after that point. Is that we are on track to submit the SBLA this year. I personally, when I was in the States, was reviewing some of the final modules in the coming weeks, you know, before 2026 closes out, we'll submit that. And so what Dr. Soon-Sheng and I said earlier in the year, what we reemphasize in that press release, I'm here today to tell you that we're on the final stretches of that as well. And that's a big game changer for us.

Roger Song, Analyst — Jefferies

Got it. And then we remember your interim data is very impressive, right? And then everyone's going to do the math, 0.1, what that means. So maybe can you just say what could be the clinically meaningful CR at six months delta compared to the BCG alone?

Richard Adcock, CEO

Yeah, I actually can't provide any more on that one, because literally, we're in conversations with the Congresses, and they're asking us to not go deeper on all of those pieces from those. And so I want to make sure that we are able to obtain those spots. But we're happy.

Roger Song, Analyst — Jefferies

Yeah. And then maybe just on the control arm, so do you see that very consistent with the historical performance, or you cannot say further?

Richard Adcock, CEO

You know, I think if you look at those, there's been multiple trials that have run in BCG, and we're expecting it to come out in that same type of a range. But again, I can't go into details. As we sit here today, I can just tell you it's met its endpoint. It's got a very strong statistical significance, and we're now just working through where's the best place to present that at.

Roger Song, Analyst — Jefferies

Got it. And then six months CR is the primary endpoint. Any other endpoint or follow-up duration you need before you can submit the FBLA?

Richard Adcock, CEO

Yeah, so the primary endpoint is six-month CR, and the FDA has told us in writing it is a registrational intent trial, and that's what they want to see. We will provide duration data that we have on those. We'll continue to update it just like we did in the unresponsive setting. We provided to them what we had, provided the KM curves when those were out, and we've updated them since, just as we presented the U.S. one in current label is 47 months and ongoing. Europe is 53 months and ongoing, and so that's a. When you have a drug that lasts as long as this, it's kind of a forever updating piece.

Roger Song, Analyst — Jefferies

Okay, got it. All right, maybe we'll have a couple more minutes, rapid fire. So how's the business outside the U.S., and then, you know, when are we going to see more meaningful revenue coming from ex-U.S.?

Richard Adcock, CEO

Yeah, so not ImmunityBio, but everybody woke up one morning and MFN came into the United States, and that changed the way we had to approach Europe. We literally had a very well-thought-out baked plan that we were ready to launch, and I read that and said, okay, we've got to all stop because I could literally go there, sell one vial, and cut my U.S. prices by 50%, which would make no sense for everybody. I am proud to say that within... Weeks or days almost of getting the, because MFN now went from an executive order, again, not related to us, but for everybody, to actually in statute or maybe not in statute, but in policy. As soon as that was released, we worked with our fantastic distributors, and we had that out there because we knew what we had to do, and so we immediately were able to bring that forward in collaboration with them in Germany and Austria, and right away we had immediate sales. And so that's what we just reported out as well. Again, all of this is happening in the now. So when we say now, literally in these recent days as we go through those, it's still uncharted water throughout all of those. I'm happy with that there is now something in an HHS policy that we can point to because it removes all of the what are we going to do, what are we not going to do phase. I can tell you that I've personally had some of these conversations with HTA authorities and others, and what they've generally said is, boy, since MFN has come out, it's like 40 or 50 drugs have either got approved and not launched and or got withdrawn in Europe. Europe is feeling the impact of that, and so we have to work through these, and that's what we're doing, and we're having all of these conversations, but when all you had was kind of a shifting line in the sand, you couldn't even start the conversation, and so now as of, I think it was the third week of October, we're able to start those, and right away, we were able to see, because they were as ready as we were, and we were able to launch and go in Germany right away.

Roger Song, Analyst — Jefferies

Excellent. Last minute, the cash, and then how should we think about the pipeline build and the next priority? Particularly, I think one specific is the papillary only naive population.

Richard Adcock, CEO

Yeah. So we reported the quarter out at $334 million, and for us, it's a great spot, again, with those pieces. So we've been managing cash well on all of those pieces. But I think in looking at that, everything that I just told you we did, and we're still in that cast position. So I'm feeling really strong about those. As it relates to those, what I'll end you with, because I see the lights flashing. The way to think about Immunity Bio is that we're not an Inc. Tiva-only company. We're not a bladder-only company. And a lot of people want to pigeonhole that and say that's what it is. That's not. Inc. Tiva can be used across multiple franchises. So what I always tell folks is think about it. We believe we're going to have a strong bladder franchise because it's now approved in 35 countries. We're going to have a strong lung franchise. We're approved in two countries. We're running trials to be able to add more in that one. The work we're doing in infectious disease with specifically around sepsis is incredibly exciting. Cleveland Clinic will be one of the first ones to open that trial. It's authorized by the FDA. It's a blinded randomized control trial phase two, which when the FDA first asked, I was like, geez, it's a phase two, a blinded randomized control trial. That's a, that's a reach. But it's actually a blessing because we're going to have very objective data. But my. I don't say my favorite part because it's hard to say favorite with sepsis, but maybe the bright side of this is it's a 28-day readout because sepsis is such a short disease, and you have a short, short time impact on those, and it's very discreet. It's a yes-no type thing, and so when we sit down, and Dr. Soon-Sheng and myself flew to Cleveland Clinic, and we presented it to them, and literally, they're like, we've been treating sepsis wrong. You're suggesting that we treat it as an immune disorder, and we've been treating it as an infection only. It really is the immune system that we have to build through those. And so, yes, we'll stay with standard of care to treat the infection, but we got to treat the underlying immune system. And so, they're really excited and collaborating with us to bring this forward. And so, that should be coming live at their sites anytime as well as others.

Roger Song, Analyst — Jefferies

Excellent. Thank you, everyone. Thank you, Rich. Thank you so much.